Prelude Capital Management’s Organogenesis Holdings ORGO Stock Holding History

Prelude Capital Management’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,008	Closed	-$33.2K	–	1448
2026 Q1	$33.2K	Buy	+14,008	New	+$48.5K	﹤0.01%	1146
2025 Q1	–	Sell	-10,200	Closed	-$32.6K	–	1442
2024 Q4	$32.6K	Buy	+10,200	New	+$34.2K	﹤0.01%	1164
2023 Q2	–	Sell	-10,043	Closed	-$21.4K	–	1294
2023 Q1	$21.4K	Sell	10,043 -5,998	-37%	-$14.8K	﹤0.01%	1045
2022 Q4	$43.1K	Sell	16,041 -1,983	-11%	-$5.78K	﹤0.01%	1144
2022 Q3	$58K	Buy	+18,024	New	+$81.4K	﹤0.01%	1218

Other funds holding ORGO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Prelude Capital Management's ORGO Position: Q2 2026 in Review

Prelude Capital Management sold out of Organogenesis Holdings (ORGO) in Q2 2026, closing a stake of 14,008 shares — an estimated $33.2K sold.

Prelude Capital Management first reported a position in ORGO in Q3 2022 and held it in 5 quarters. The position peaked at $58K in Q3 2022. 134 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

Prelude Capital Management reported no remaining Organogenesis Holdings position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 14,008 Organogenesis Holdings shares in Q2 2026, an estimated $33.2K.
Prelude Capital Management first reported a position in Organogenesis Holdings in Q3 2022 and held it in 5 quarters.
Prelude Capital Management's Organogenesis Holdings position peaked at $58K in Q3 2022.
134 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.